Concourse Financial Group Securities, Inc. Dyne Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$31.94 - $47.04 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$23.65 - $35.63 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$13.06 - $29.18 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$6.62 - $13.64 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$8.6 - $12.18 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$8.6 - $12.18 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$8.53 - $14.28 $0 - $0
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$9.37 - $13.8 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$7.2 - $15.17 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$4.36 - $10.5 $0 - $0
Q1 2022 May 09, 2022	BUY	$6.52 - $12.27 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$11.89 - $16.07 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$15.6 - $21.46 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$15.94 - $22.33 $0 - $0
Q1 2021 May 13, 2021	BUY	$14.0 - $29.3 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$16.81 - $23.94 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$20.0 - $23.9 $0 - $0

Others Institutions Holding DYN

# of Institutions

209

Shares Held

102M

Call Options Held

234K

Put Options Held

238K

Atlas Venture Life Science Advisors, LLC

8.02M
Shares

$192 Million
35.54% of portfolio
Black Rock Inc. New York, NY

7.39M
Shares

$177 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.86M
Shares

$165 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

6.82M
Shares

$164 Million
3.9% of portfolio
Janus Henderson Group PLC London, X0

6.81M
Shares

$163 Million
0.13% of portfolio

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.24B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account